CD274 and gastric cancer: Forty percent of GC cases are PD-L1 positive (143), and preclinical studies suggest high CD73 expression in PD-1/PD-L1 expressing tumors may identify patients that would benefit from combination anti-PD-1/PD-L1 therapy and CD73 and/or A2AR blockade (122, 123).